Adherence to lifestyle recommendations in cancer survivors Cancer
Conditions
Interventions
Current interventions as of 24/01/2023:
Cancer survivors will receive a blended care intervention, administered by their general practitioner or a practice nurse (PN). The blended care intervention
around 40 GPs will be computer randomized using the OpenEpi open source program (OpenEpi, 2013) to either intervention of control group by an inde
Sponsors
Netherlands Organisation for Health Research and Development
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients who have successfully completed the primary treatment for cancer (e.g. radiotherapy, chemotherapy, surgery), with the last treatment to have been between 6 weeks ago and 3 years ago, or belong to a watchful waiting condition (e.g. option for prostate cancer patients) 2. 18 years of age and older 3. Able to read and speak Dutch 4. Internet access and at least minimal internet experience 5. Access to a computer or tablet
Exclusion criteria
Exclusion criteria: 1. Patients with a serious medical, psychiatric, or cognitive disease that would interfere with participation (e.g. Alzheimer’s disease, blindness) 2. Patients who did not complete primary treatment or who were not treated with curative intent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| At baseline, 6 months and 12 months: 1. Physical activity (PA) will be assessed with the SQUASH questionnaire (Wendel-Vos et al., 2003) 2. Smoking behavior will be assessed by a validated 7-days point prevalence abstinence questionnaire (Mudde et al., 2000) 3. Alcohol consumption will be assessed using a standardized scale (GGD, 2003) 4. Dietary behaviors will be assessed using a validated food frequency questionnaire (VanAssema et al., 2002) | — |
Secondary
| Measure | Time frame |
|---|---|
| Current secondary outcome measures as of 24/01/2023: 1. Effects on self-reported health-related Quality of Life will be assessed with the EORTC QLQ-C30 at baseline, 6 months and 12 months; self-reported distress will be assessed with the Hospital Anxiety and Depression Scale (HADS) at baseline, 6 months and 12 months; and self-reported fatigue will be assessed with the Checklist Individual Strength (CIS) at baseline, 6 months and 12 months 2. Biomarkers, including TC/HDL cholesterol, blood glucose and blood pressure are assessed by means of clinical measurement at 6 months 3. Evaluation of health-related costs based on self-reported Medical consumption (assessed with the iMTA-MCQ at 6 months); self-reported Productivity costs (assessed with the iMTA-PCQ at 6 months); and QALY (assessed with the EQ-5D-5L at 6 months) 4. Process evaluation based on self-report data assessed by means of a process evaluation questionnaire at 6 months _____ Previous secondary outcome measures: 1. Effects on self-reported health-related Quality of Life will be assessed with the EORTC QLQ-C30 at baseline, 6 months and 12 months; self-reported distress will be assessed with the Hospital Anxiety and Depression Scale (HADS) at baseline, 6 months and 12 months; and self-reported fatigue will be assessed with the Checklist Individual Strength (CIS) at baseline, 6 months and 12 months 2. Biomarkers, including TC/HDL cholesterol, blood glucose and blood pressure are assessed by means of clinical measurement at baseline and 6 months 3. Evaluation of health-related costs based on self-reported Medical consumption (assessed with the iMTA-MCQ at 6 months); self-reported Productivity costs (assessed with the iMTA-PCQ at 6 months); and QALY (assessed with the EQ-5D-5L at 6 months) 4. Process evaluation based on self-report data assessed by means of a process evaluation questionnaire at 6 months | — |
Countries
Netherlands
Contacts
Public ContactMichelle Smits
Outcome results
None listed